WELCOME TO THE ASCERTAIN POLICY SUPPORT TOOL!
Explore ASCERTAIN Models
About ASCERTAIN
The ASCERTAIN Policy Support Tool is an online platform for exploring the pricing, clinical and economic implications of new health technologies. It includes five models: the Access-Based Pricing Model, CAR-T Cost-Effectiveness Model, Precision Cancer Medicine Model, NGS diagnostics core model and Cost-Effectiveness Threshold Model. Their results can inform negotiations and decisions about medicines and medical devices.
The web interface lets you explore scenarios by changing the parameters of each model. You can review the resulting calculations and download them as reports.
Choose a model and start an assessment to see its introduction page. It includes “How to work with this model” and “Model Documentation”, with guidance on its purpose, inputs and results.
The tool is intended for a broad range of stakeholders. Health authorities and insurers can use it to explore evidence for decisions about access to innovative health technologies. Patients, clinicians, industry and hospitals can also use the models to examine pricing, effectiveness and cost-effectiveness scenarios.
The inputs depend on the model. Some require numerical values, while others let you choose from predefined options. Review the model documentation and any prefilled values before running a calculation.
Assessments are private by default. Other users can access an assessment only if it is explicitly shared with them. Sharing permissions determine whether they can view or edit it. For more information about how your data is handled, read our Privacy Notice.
You can save different versions of an assessment and compare completed model runs. You can also download an assessment report as a Word or PDF file.
ASCERTAIN brings together publicly accessible models for pricing, health technology assessment and reimbursement in one tool. It aims to support more efficient evaluation and decision-making by making assumptions and results transparent. This can inform discussions about reasonable, reimbursable prices and access to innovative health technologies.
The tool was developed with input from representatives of stakeholder groups involved in pricing and reimbursement. Their perspectives help make uncertainties along the path from marketing authorisation to reimbursement more visible.
Our Partners
